Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study to Investigate the Safety and Efficacy of TE-8105 Administered Subcutaneously in Participants With Overweight or Obesity

NCT07857473 is registered in ClinicalTrials.gov with Immunwork, Inc. as lead sponsor.

NCT NCT07857473
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07857473 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-Blind, Placebo-Controlled Phase 2b Study to Investigate the Safety and Efficacy of TE-8105 Administered Subcutaneously in Participants With Overweight or Obesity
Lead sponsor
Immunwork, Inc.
Phase
Phase 2
Overall status
Not yet recruiting
Start date
October 31, 2026
Completion date
February 29, 2028
Enrollment
204 (estimated)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

overweight and obesity